Green Technology Metals (GT1:AU) has announced Seymour Concentrate Produces Battery Grade Lithium Hydroxide
Download the PDF here.
This post appeared first on investingnews.com
Alvopetro Energy Ltd. (TSXV: ALV,OTC:ALVOF) (OTCQX: ALVOF) announces an operational update and financial results for the three and six months ended June 30 2025.
All references herein to $ refer to United States dollars, unless otherwise stated and all tabular amounts are in thousands of United States dollars, except as otherwise noted.
President & CEO, Corey C. Ruttan commented:
‘Q2 included our first quarter of sales from our recently added Western Canadian assets and overall sales volumes continued to be very strong averaging 2,436 boepd, up 50% from Q2 2024, and consistent with Q1 2025. We have a considerable amount of activity underway and we are looking forward to an exciting Q3 with the completion and tie-in of our 183-D4 well, our Caburé Unit development wells, and our two most recently drilled multi-lateral wells in Western Saskatchewan . Our 2025 capital program is organically funded and focused on high rate of return opportunities in Brazil and also now in the Western Canadian Sedimentary Basin.’
Operational Update
July Sales Volumes
|
Natural gas, NGLs and crude oil sales: |
July 2025 |
June 2025 |
Q2 2025 |
|
Brazil: |
|||
|
Natural gas (Mcfpd), by field: |
|||
|
Caburé |
11,122 |
11,804 |
11,811 |
|
Murucututu |
1,751 |
1,446 |
1,191 |
|
Total natural gas (Mcfpd) |
12,873 |
13,250 |
13,002 |
|
NGLs (bopd) |
130 |
147 |
128 |
|
Oil (bopd) |
9 |
9 |
3 |
|
Total (boepd) – Brazil |
2,284 |
2,365 |
2,298 |
|
Canada: |
|||
|
Oil (bopd) – Canada |
134 |
149 |
138 |
|
Total Company – boepd (1) |
2,418 |
2,514 |
2,436 |
|
(1) Alvopetro reported volumes are based on sales volumes which, due to the timing of sales deliveries, may differ from production volumes. |
July sales volumes averaged 2,418 boepd, including 2,284 boepd from Brazil (with natural gas sales of 12.9 MMcfpd, associated natural gas liquids sales from condensate of 130 bopd, and oil sales of 9 bopd) and 134 bopd from oil sales in Canada , based on field estimates.
Quarterly Natural Gas Pricing Update
Effective August 1, 2025 , our natural gas price under our long-term gas sales agreement was adjusted to BRL1.90 /m 3 and will apply to all natural gas sales from August 1, 2025 to October 31, 2025 . Based on our average heat content to date and the July 31, 2025 BRL/USD exchange rate of 5.60, our expected realized price at the new contracted price is $10.27 /Mcf, net of applicable sales taxes, a decrease of 3% from the Q2 2025 realized price of $10.62 /Mcf due mainly to reduced Henry Hub and Brent prices in the second quarter. Amounts ultimately received in equivalent USD will be impacted by exchange rates in effect during the period August 1, 2025 to October 31, 2025 .
Development Activities – Brazil
On our 100% owned Murucututu field, the 183-D4 well was drilled in the second quarter to a total measured depth of 3,072 metres. The well encountered the Caruaçu Member of the Maracangalha Formation 106 metres structurally updip of our 183-A3 well which has been on production since the fourth quarter of 2024. Based on cased-hole gamma ray logs and normalized gas while drilling, the well encountered potential natural gas pay in the Caruaçu Member of the Maracangalha Formation, with an aggregate 61 metres total vertical depth (‘TVD’) of potential natural gas pay between 2,439 and 2,838 meters TVD. We’ve now completed the well in seven intervals and expect to have the well on production later in the third quarter. A total of $3.3 million of capital expenditures are estimated on the field in the second half of 2025, including costs for the 183-D4 completion.
Our joint development on the unitized area (‘the Unit’) which includes our Caburé field commenced in the second quarter and three wells (1.7 net) have now been drilled. The fourth well (0.6 net) is expected to be drilled later in the third quarter. Alvopetro’s share of these planned unit development costs in the second half of 2025 is anticipated to be $5.5 million . The timing of drilling the fifth development well (0.6 net) is subject to the receipt of all necessary regulatory approvals.
Development Activities – Western Canada
In June, we further expanded our joint Mannville focused land based to 17,780 gross acres (8,890 net acres) and in July, two additional multi-lateral wells (1.0 net) were drilled with an aggregate of over 19 kilometers of open hole reservoir contact. Both wells will now be completed and equipped and are expected to be on production later in the third quarter. We expect to drill our next two multi-lateral wells (1.0 net) starting later this year.
Financial and Operating Highlights – Second Quarter of 2025
- Average daily sales in Q2 2025 were 2,436 boepd (+50% from Q2 2024 and consistent with Q1 2025 sales of 2,446 boepd). In Brazil , daily sales averaged 2,298 boepd (+41% compared to Q2 2024) and in Canada , oil sales commenced in April 2025 , contributing 138 bopd in the quarter.
- Our average realized natural gas price was $10.62 /Mcf in Q2 2025 (-10% from Q2 2024 and +2% from Q1 2025). Our overall averaged realized sales price per boe was $63.20 /boe (-12% from Q2 2024 and -1% from Q1 2025).
- With higher sales volumes, our natural gas, oil and condensate revenue increased to $14.0 million (+31% from Q2 2024).
- Our operating netback in the quarter was $54.72 per boe, a decrease of $9.58 per boe compared to Q2 2024 due mainly to lower realized sales prices as well as higher royalties. Compared to Q1 2025, our operating netback increased $3.95 per boe with lower royalties partially offset by lower realized prices.
- We generated funds flows from operations of $10.4 million ( $0.28 per basic and $0.27 per diluted share), increases of $2.5 million compared to Q2 2024 and $1.1 million compared to Q1 2025.
- We reported net income of $6.8 million ( $0.18 per basic and diluted share), an increase of $4.5 million compared to Q2 2024 due to higher sales volumes as well as foreign exchange gains (compared to foreign exchange losses in Q2 2024), partially offset by lower realized prices and higher royalties, production expenses, depletion and depreciation expense and tax expense.
- Capital expenditures totaled $9.0 million , including drilling costs for the 183-D4 well on Alvopetro’s 100% Murucututu field as well as Alvopetro’s share of costs incurred on unit development, including costs for two (1.1 net) of five development wells (2.8 net) which commenced drilling in the quarter.
- Our working capital surplus was $6.8 million as of June 30, 2025 , decreasing $2.9 million from March 31, 2025 .
The following table provides a summary of Alvopetro’s financial and operating results for the periods noted. The consolidated financial statements with the Management’s Discussion and Analysis (‘MD&A’) are available on our website at www.alvopetro.com and will be available on the SEDAR+ website at www.sedarplus.ca .
|
As at and Three Months Ended June 30, |
As at and Six Months Ended June 30, |
|||||
|
2025 |
2024 |
Change |
2025 |
2024 |
Change (%) |
|
|
Financial |
||||||
|
($000s, except where noted) |
||||||
|
Natural gas, oil and condensate sales |
14,010 |
10,672 |
31 |
28,023 |
22,424 |
25 |
|
Net income |
6,830 |
2,350 |
191 |
12,900 |
6,900 |
87 |
|
Per share – basic ($) (1) |
0.18 |
0.06 |
200 |
0.35 |
0.19 |
84 |
|
Per share – diluted ($) (1) |
0.18 |
0.06 |
200 |
0.34 |
0.18 |
89 |
|
Cash flows from operating activities |
10,473 |
8,860 |
18 |
19,290 |
17,073 |
13 |
|
Per share – basic ($) (1) |
0.28 |
0.24 |
17 |
0.52 |
0.46 |
13 |
|
Per share – diluted ($) (1) |
0.28 |
0.24 |
17 |
0.51 |
0.45 |
13 |
|
Funds flow from operations (2) |
10,366 |
7,910 |
31 |
19,588 |
16,423 |
19 |
|
Per share – basic ($) (1) |
0.28 |
0.21 |
33 |
0.53 |
0.44 |
20 |
|
Per share – diluted ($) (1) |
0.27 |
0.21 |
29 |
0.52 |
0.44 |
18 |
|
Dividends declared |
3,660 |
3,296 |
11 |
7,303 |
6,592 |
11 |
|
Per share (1) (2) |
0.10 |
0.09 |
11 |
0.20 |
0.18 |
11 |
|
Capital expenditures |
8,986 |
3,437 |
161 |
17,361 |
5,876 |
195 |
|
Cash and cash equivalents |
15,001 |
19,681 |
(24) |
15,001 |
19,681 |
(24) |
|
Net working capital (2) |
6,838 |
14,692 |
(53) |
6,838 |
14,692 |
(53) |
|
Weighted average shares outstanding |
||||||
|
Basic (000s) (1) |
37,261 |
37,286 |
– |
37,278 |
37,282 |
– |
|
Diluted (000s) (1) |
37,795 |
37,600 |
1 |
37,770 |
37,647 |
– |
|
Operations |
||||||
|
Average daily sales volumes (3) : |
||||||
|
Brazil: |
||||||
|
Natural gas (Mcfpd), by field: |
||||||
|
Caburé (Mcfpd) |
11,811 |
8,822 |
34 |
11,761 |
9,029 |
30 |
|
Murucututu (Mcfpd) |
1,191 |
422 |
182 |
1,639 |
426 |
285 |
|
Total natural gas (Mcfpd) |
13,002 |
9,244 |
41 |
13,400 |
9,455 |
42 |
|
NGLs – condensate (bopd) |
128 |
76 |
68 |
131 |
77 |
70 |
|
Oil (bopd) |
3 |
12 |
(75) |
7 |
12 |
(42) |
|
Total (boepd) – Brazil |
2,298 |
1,629 |
41 |
2,371 |
1,665 |
42 |
|
Canada: |
||||||
|
Oil (bopd) – Canada |
138 |
– |
– |
69 |
– |
– |
|
Total Company (boepd) |
2,436 |
1,629 |
50 |
2,440 |
1,665 |
47 |
|
Average realized prices (2) : |
||||||
|
Natural gas ($/Mcf) |
10.62 |
11.83 |
(10) |
10.53 |
12.21 |
(14) |
|
NGLs – condensate ($/bbl) |
72.32 |
92.27 |
(22) |
76.78 |
90.06 |
(15) |
|
Oil ($/bbl) |
47.10 |
71.87 |
(34) |
48.31 |
68.54 |
(30) |
|
Total ($/boe) |
63.20 |
71.97 |
(12) |
63.43 |
74.00 |
(14) |
|
Operating netback ($/boe) (2) |
||||||
|
Realized sales price |
63.20 |
71.97 |
(12) |
63.43 |
74.00 |
(14) |
|
Royalties |
(2.97) |
(1.94) |
53 |
(5.28) |
(1.98) |
167 |
|
Production expenses |
(5.37) |
(5.73) |
(6) |
(5.34) |
(6.77) |
(21) |
|
Transportation expenses |
(0.14) |
– |
– |
(0.07) |
– |
– |
|
Operating netback |
54.72 |
64.30 |
(15) |
52.74 |
65.25 |
(19) |
|
Operating netback margin (2) |
87 % |
89 % |
(2) |
83 % |
88 % |
(6) |
|
Notes: |
|
|
(1) |
Per share amounts are based on weighted average shares outstanding other than dividends per share, which is based on the number of common shares outstanding at each dividend record date. The weighted average number of diluted common shares outstanding in the computation of funds flow from operations and cash flows from operating activities per share is the same as for net income per share. |
|
(2) |
See ‘Non-GAAP and Other Financial Measures’ section within this news release. |
|
(3) |
Alvopetro reported volumes are based on sales volumes which, due to the timing of sales deliveries, may differ from production volumes. |
Q2 2025 Results Webcast
Alvopetro will host a live webcast to discuss our Q2 2025 financial results at 8:00 am Mountain time on Thursday August 7, 2025. Details for joining the event are as follows:
DATE: August 7, 2025
TIME : 8:00 AM Mountain/ 10:00 AM Eastern
LINK: https://us06web.zoom.us/j/87200931927
DIAL-IN NUMBERS: https://us06web.zoom.us/u/kdLidYPIoO
WEBINAR ID: 872 0093 1927
The webcast will include a question-and-answer period. Online participants will be able to ask questions through the Zoom portal. Dial-in participants can email questions directly to socialmedia@alvopetro.com .
Corporate Presentation
Alvopetro’s updated corporate presentation is available on our website at:
http://www.alvopetro.com/corporate-presentation .
Social Media
Follow Alvopetro on our social media channels at the following links:
Twitter – https://twitter.com/AlvopetroEnergy
Instagram – https://www.instagram.com/alvopetro/
LinkedIn – https://www.linkedin.com/company/alvopetro-energy-ltd
Alvopetro Energy Ltd. is deploying a balanced capital allocation model where we seek to reinvest roughly half our cash flows into organic growth opportunities and return the other half to stakeholders. Alvopetro’s organic growth strategy is to focus on the best combinations of geologic prospectivity and fiscal regime. Alvopetro is balancing capital investment opportunities in Canada and Brazil where we are building off the strength of our Caburé and Murucututu natural gas fields and the related strategic midstream infrastructure.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.
Abbreviations:
|
$000s |
= |
thousands of U.S. dollars |
|
boepd |
= |
barrels of oil equivalent (‘boe’) per day |
|
bopd |
= |
barrels of oil and/or natural gas liquids (condensate) per day |
|
BRL |
= |
Brazilian Real |
|
e 3 m 3 /d |
= |
thousand cubic metre per day |
|
m 3 |
= |
cubic metre |
|
m 3 /d |
= |
cubic metre per day |
|
Mcf |
= |
thousand cubic feet |
|
Mcfpd |
= |
thousand cubic feet per day |
|
MMcf |
= |
million cubic feet |
|
MMcfpd |
= |
million cubic feet per day |
|
NGLs |
= |
natural gas liquids (condensate) |
|
Q1 2025 |
= |
three months ended March 31, 2025 |
|
Q2 2024 |
= |
three months ended June 30, 2024 |
|
Q2 2025 |
= |
three months ended June 30, 2025 |
|
USD |
= |
United States dollars |
|
GAAP or IFRS |
= |
IFRS Accounting Standards |
Non-GAAP and Other Financial Measures
This news release contains references to various non-GAAP financial measures, non-GAAP ratios, capital management measures and supplementary financial measures as such terms are defined in National Instrument 52-112 Non-GAAP and Other Financial Measures Disclosure . Such measures are not recognized measures under GAAP and do not have a standardized meaning prescribed by IFRS and might not be comparable to similar financial measures disclosed by other issuers. While these measures may be common in the oil and gas industry, the Company’s use of these terms may not be comparable to similarly defined measures presented by other companies. The non-GAAP and other financial measures referred to in this report should not be considered an alternative to, or more meaningful than measures prescribed by IFRS and they are not meant to enhance the Company’s reported financial performance or position. These are complementary measures that are used by management in assessing the Company’s financial performance, efficiency and liquidity and they may be used by investors or other users of this document for the same purpose. Below is a description of the non-GAAP financial measures, non-GAAP ratios, capital management measures and supplementary financial measures used in this news release. For more information with respect to financial measures which have not been defined by GAAP, including reconciliations to the closest comparable GAAP measure, see the ‘ Non-GAAP Measures and Other Financial Measures ‘ section of the Company’s MD&A which may be accessed through the SEDAR+ website at www.sedarplus.ca .
Non-GAAP Financial Measures
Operating Netback
Operating netback is calculated as natural gas, oil and condensate revenues less royalties, production expenses, and transportation expenses. This calculation is provided in the ‘ Operating Netback ‘ section of the Company’s MD&A using our IFRS measures. The Company’s MD&A may be accessed through the SEDAR+ website at www.sedarplus.ca . Operating netback is a common metric used in the oil and gas industry used to demonstrate profitability from operations.
Non-GAAP Financial Ratios
Operating Netback per boe
Operating netback is calculated on a per unit basis, which is per barrel of oil equivalent (‘boe’). It is a common non-GAAP measure used in the oil and gas industry and management believes this measurement assists in evaluating the operating performance of the Company. It is a measure of the economic quality of the Company’s producing assets and is useful for evaluating variable costs as it provides a reliable measure regardless of fluctuations in production. Alvopetro calculated operating netback per boe as operating netback divided by total sales volumes (boe). This calculation is provided in note 3 of the interim condensed consolidated financial statements and in the ‘ Operating Netback ‘ section of the Company’s MD&A using our IFRS measures. The Company’s MD&A may be accessed through the SEDAR+ website at www.sedarplus.ca . Operating netback is a common metric used in the oil and gas industry used to demonstrate profitability from operations on a per boe basis.
Operating netback margin
Operating netback margin is calculated as operating netback per boe divided by the realized sales price per boe. Operating netback margin is a measure of the profitability per boe relative to natural gas, oil and condensate sales revenues per boe and is calculated as follows:
|
Three Months Ended June 30, |
Six Months Ended June 30, |
|||
|
2025 |
2024 |
2025 |
2024 |
|
|
Operating netback – $ per boe |
54.72 |
64.30 |
52.74 |
65.25 |
|
Average realized price – $ per boe |
63.20 |
71.97 |
63.43 |
74.00 |
|
Operating netback margin |
87 % |
89 % |
83 % |
88 % |
Funds Flow from Operations Per Share
Funds flow from operations per share is a non-GAAP ratio that includes all cash generated from operating activities and is calculated before changes in non-cash working capital, divided by the weighted average shares outstanding for the respective period. For the periods reported in this news release the cash flows from operating activities per share and funds flow from operations per share is as follows:
|
Three Months Ended June 30, |
Six Months Ended June 30, |
|||
|
$ per share |
2025 |
2024 |
2025 |
2024 |
|
Per basic share: |
||||
|
Cash flows from operating activities |
0.28 |
0.24 |
0.52 |
0.46 |
|
Funds flow from operations |
0.28 |
0.21 |
0.53 |
0.44 |
|
Per diluted share: |
||||
|
Cash flows from operating activities |
0.28 |
0.24 |
0.51 |
0.45 |
|
Funds flow from operations |
0.27 |
0.21 |
0.52 |
0.44 |
Capital Management Measures
Funds Flow from Operations
Funds flow from operations is a non-GAAP capital management measure that includes all cash generated from operating activities and is calculated before changes in non-cash working capital. The most comparable GAAP measure to funds flow from operations is cash flows from operating activities. Management considers funds flow from operations important as it helps evaluate financial performance and demonstrates the Company’s ability to generate sufficient cash to fund future growth opportunities. Funds flow from operations should not be considered an alternative to, or more meaningful than, cash flows from operating activities however management finds that the impact of working capital items on the cash flows reduces the comparability of the metric from period to period. A reconciliation of funds flow from operations to cash flows from operating activities is as follows:
|
Three Months Ended June 30, |
Six Months Ended June 30, |
|||
|
2025 |
2024 |
2025 |
2024 |
|
|
Cash flows from operating activities |
10,473 |
8,860 |
19,290 |
17,073 |
|
Changes in non-cash working capital |
(107) |
(950) |
298 |
(650) |
|
Funds flow from operations |
10,366 |
7,910 |
19,588 |
16,423 |
Net Working Capital
Net working capital is computed as current assets less current liabilities. Net working capital is a measure of liquidity, is used to evaluate financial resources, and is calculated as follows:
|
As at June 30, |
|||
|
2025 |
2024 |
||
|
Total current assets |
22,915 |
25,300 |
|
|
Total current liabilities |
(16,077) |
(10,608) |
|
|
Net working capital |
6,838 |
14,692 |
|
Supplementary Financial Measures
‘ Average realized natural gas price – $/Mcf ‘ is comprised of natural gas sales as determined in accordance with IFRS, divided by the Company’s natural gas sales volumes.
‘ Average realized NGL – condensate price – $/bbl ‘ is comprised of condensate sales as determined in accordance with IFRS, divided by the Company’s NGL sales volumes from condensate.
‘ Average realized oil price – $/bbl ‘ is comprised of oil sales as determined in accordance with IFRS, divided by the Company’s oil sales volumes.
‘ Average realized price – $/boe ‘ is comprised of natural gas, condensate and oil sales as determined in accordance with IFRS, divided by the Company’s total natural gas, NGL and oil sales volumes (barrels of oil equivalent).
‘ Dividends per share ‘ is comprised of dividends declared, as determined in accordance with IFRS, divided by the number of shares outstanding at the dividend record date.
‘ Royalties per boe ‘ is comprised of royalties, as determined in accordance with IFRS, divided by the total natural gas, NGL and oil sales volumes (barrels of oil equivalent).
‘ Production expenses per boe ‘ is comprised of production expenses, as determined in accordance with IFRS, divided by the total natural gas, NGL and oil sales volumes (barrels of oil equivalent).
‘ Transportation expenses per boe ‘ is comprised of transportation expenses, as determined in accordance with IFRS, divided by the total natural gas, NGL and oil sales volumes (barrels of oil equivalent).
BOE Disclosure
The term barrels of oil equivalent (‘boe’) may be misleading, particularly if used in isolation. A boe conversion ratio of six thousand cubic feet per barrel (6 Mcf/bbl) of natural gas to barrels of oil equivalence is based on an energy equivalency conversion method primarily applicable at the burner tip and does not represent a value equivalency at the wellhead. All boe conversions in this news release are derived from converting gas to oil in the ratio mix of six thousand cubic feet of gas to one barrel of oil.
Contracted Natural Gas Volumes
The 2025 contracted daily firm volumes under Alvopetro’s long-term gas sales agreement of 400 e 3 m 3 /d (before any provisions for take or pay allowances) represents contracted volumes based on contract referenced natural gas heating value. Alvopetro’s reported natural gas sales volumes are prior to any adjustments for heating value of Alvopetro natural gas. Alvopetro’s natural gas is approximately 7.8% higher than the contract reference heating value. Therefore, to satisfy the contractual firm deliveries Alvopetro would be required to deliver approximately 371e 3 m 3 /d (13.1MMcfpd).
Well Results
Data obtained from the 183-D4 well identified in this press release, including hydrocarbon shows, cased-hole logging data, and potential net pay should be considered preliminary until testing, detailed analysis and interpretation has been completed. Hydrocarbon shows can be seen during the drilling of a well in numerous circumstances and do not necessarily indicate a commercial discovery or the presence of commercial hydrocarbons in a well. There is no representation by Alvopetro that the data relating to the 183-D4 well contained in this press release is necessarily indicative of long-term performance or ultimate recovery. The reader is cautioned not to unduly rely on such data as such data may not be indicative of future performance of the well or of expected production or operational results for Alvopetro in the future.
Forward-Looking Statements and Cautionary Language
This news release contains forward-looking information within the meaning of applicable securities laws. The use of any of the words ‘will’, ‘expect’, ‘intend’, ‘plan’, ‘may’, ‘believe’, ‘estimate’, ‘forecast’, ‘anticipate’, ‘should’ and other similar words or expressions are intended to identify forward-looking information. Forward‐looking statements involve significant risks and uncertainties, should not be read as guarantees of future performance or results, and will not necessarily be accurate indications of whether or not such results will be achieved. A number of factors could cause actual results to vary significantly from the expectations discussed in the forward-looking statements. These forward-looking statements reflect current assumptions and expectations regarding future events. Accordingly, when relying on forward-looking statements to make decisions, Alvopetro cautions readers not to place undue reliance on these statements, as forward-looking statements involve significant risks and uncertainties. More particularly and without limitation, this news release contains forward-looking statements concerning the expected natural gas price, gas sales and gas deliveries under Alvopetro’s long-term gas sales agreement, future production and sales volumes, the expected timing of production commencement from certain wells, plans relating to the Company’s operational activities, proposed exploration and development activities and the timing for such activities, capital spending levels, future capital and operating costs, the timing and taxation of dividends and plans for dividends in the future, anticipated timing for upcoming drilling and testing of other wells, and projected financial results. Forward-looking statements are necessarily based upon assumptions and judgments with respect to the future including, but not limited to the success of future drilling, completion, testing, recompletion and development activities and the timing of such activities, the performance of producing wells and reservoirs, well development and operating performance, expectations and assumptions concerning the timing of regulatory licenses and approvals, equipment availability, environmental regulation, including regulations relating to hydraulic fracturing and stimulation, the ability to monetize hydrocarbons discovered, the outlook for commodity markets and ability to access capital markets, foreign exchange rates, the outcome of any disputes, the outcome of redeterminations, general economic and business conditions, forecasted demand for oil and natural gas, the impact of global pandemics, weather and access to drilling locations, the availability and cost of labour and services, and the regulatory and legal environment and other risks associated with oil and gas operations. The reader is cautioned that assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be incorrect. Actual results achieved during the forecast period will vary from the information provided herein as a result of numerous known and unknown risks and uncertainties and other factors. Current and forecasted natural gas nominations are subject to change on a daily basis and such changes may be material. In addition, the declaration, timing, amount and payment of future dividends remain at the discretion of the Board of Directors. Although we believe that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because we can give no assurance that they will prove to be correct. Since forward looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. These include, but are not limited to, risks associated with the oil and gas industry in general (e.g., operational risks in development, exploration and production; delays or changes in plans with respect to exploration or development projects or capital expenditures; the uncertainty of reserve estimates; the uncertainty of estimates and projections relating to production, costs and expenses, reliance on industry partners, availability of equipment and personnel, uncertainty surrounding timing for drilling and completion activities resulting from weather and other factors, changes in applicable regulatory regimes and health, safety and environmental risks), commodity price and foreign exchange rate fluctuations, market uncertainty associated with trade or tariff disputes, and general economic conditions. The reader is cautioned that assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be incorrect. Although Alvopetro believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because Alvopetro can give no assurance that it will prove to be correct. Readers are cautioned that the foregoing list of factors is not exhaustive. Additional information on factors that could affect the operations or financial results of Alvopetro are included in our AIF which may be accessed on Alvopetro’s SEDAR+ profile at www.sedarplus.ca . The forward-looking information contained in this news release is made as of the date hereof and Alvopetro undertakes no obligation to update publicly or revise any forward-looking information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.
www.alvopetro.com
TSX-V: ALV, OTCQX: ALVOF
SOURCE Alvopetro Energy Ltd.
View original content: http://www.newswire.ca/en/releases/archive/August2025/06/c8138.html
News Provided by Canada Newswire via QuoteMedia
This post appeared first on investingnews.com
Investor Insight
Westport’ innovative technologies and pioneered alternative fuel delivery systems offer a compelling case for investors looking to participate in the opportunities of a low-carbon economy.
Overview
Westport (NASDAQ:WPRT,TSX:WPRT) specializes in delivering advanced fuel technologies, with a focus on heavy-duty vehicles, aimed at reducing carbon emissions without compromising engine performance. As a key player in the clean transportation space, Westport offers innovative solutions that enable internal combustion engines to operate on alternative low-carbon fuels, including natural gas, renewable natural gas (RNG), propane and hydrogen.
Westport is focused on the following transportation market opportunities:
- High-pressure Controls and Systems: Focuses on high-pressure fuel management solutions for hydrogen and other alternative fuel engines. Westport is embracing early-stage hydrogen infrastructure development and offers key components such as pressure regulators, injectors and fuel rails for both internal combustion engines and fuel cell applications. While hydrogen is key to the future decarbonization of transport, Westport’s components and solutions are already powering innovation today across a range of gaseous fuels.
In 2025, Westport completed the sale of its Light-Duty Segment to Heliaca Investments, allowing the company to strengthen its balance sheet and focus on high-growth opportunities in heavy-duty and industrial markets.
Market Position and Competitive Advantage
Westport operates in a rapidly growing and changing clean transportation market driven by stringent emission regulations, increasing fuel costs, and rising demand for sustainable mobility solutions. The company’s competitive edge lies in its proprietary HPDI technology, which uniquely delivers diesel-equivalent performance while significantly reducing carbon emissions. Westport’s joint venture with Volvo Group, under the Cespira name, enhances its ability to scale HPDI solutions globally.
Fleet operators and logistics companies are increasingly turning to alternative fuel vehicles to reduce operational costs and meet stringent ESG goals. In response, Westport continues to invest in innovation, particularly in hydrogen and renewable natural gas solutions.
Company Highlights
- Westport is a pioneer in the development and commercialization of alternative fuel delivery systems for natural gas, renewable natural gas (RNG), propane, and hydrogen-powered internal combustion engines (ICEs).
- The company is rooted in heavy-duty vehicle market, leveraging Westport’s proprietary fuel technologies to deliver reductions in carbon emissions for both commercial and passenger vehicles.
- Westport’s High-Pressure Controls and Systems segment focuses on fuel management solutions for hydrogen and other pressurized alternative fuels.
- The flagship HPDI technology, now part of the company’s Cespira joint venture with Volvo Group, enables heavy-duty trucks to operate on natural gas or hydrogen, thereby substantially lowering CO₂ emissions while delivering diesel-equivalent or better performance.
- Westport’s growth trajectory is enhanced by key collaborations, most notably via the formation of Cespira, a joint venture with Volvo Group aimed at accelerating the global adoption of the HPDI technology.
Key Technologies
HPDI Fuel System (transferred into the Cespira JV with Volvo Group)
The HPDI fuel system is engineered for heavy-duty trucks and industrial applications. By injecting high-pressure natural gas or hydrogen directly into the combustion chamber, HPDI delivers diesel-like torque and power with up to 98 percent lower CO₂ emissions when using hydrogen. This technology is critical for long-haul trucking and other high-load applications, where maintaining performance and range is essential. This technology is now owned under the Cespira JV, which generated a revenue of $16.2 million in Q3 2024.
The HPDI system features a revolutionary, patented injector with a dual concentric needle design that delivers small quantities of diesel fuel and large quantities of natural gas, at high pressure, to the combustion chamber.
High-pressure Controls and Components
Westport’s high-pressure gaseous controls segment is at the forefront of the clean energy revolution, designing, developing and producing high-demand components for transportation and industrial applications. The company partners with the world’s leading fuel cell manufacturers and companies committed to decarbonizing transport, offering versatile solutions that serve a variety of fuel types. While hydrogen is key to the future decarbonization of transport, Westport components and solutions are already powering innovation today across a range of gaseous fuels. With decades of experience, market-leading brands, and unmatched engineering expertise, the company is a leader in the market. While still small, its strategic position and innovative capabilities put Westport on the cusp of significant growth, ensuring it is the go-to choice for those shaping the future of clean energy, today and tomorrow.
Management
Westport is helmed by an accomplished executive team with extensive experience in automotive technology, alternative fuels and corporate strategy.
Dan Sceli – CEO
Dan Sceli was appointed as CEO in January of 2024. His distinguished 37-year career in the global manufacturing sector marks him as a visionary leader, whose strategic acumen and commitment to excellence have propelled companies to new heights.
Bill Larkin – CFO
Bill Larkin has been instrumental in strengthening the company’s financial position since joining in 2022. With prior experience as CFO of Fuel Systems Solutions and Westport Innovations, Larkin’s experience spans a diverse set of corporate environments ranging from entrepreneurial startups, high growth small-caps and mature multi-billion dollar enterprises across various industries.
Ashley Nuell – VP of Investor Relations
Ashley Nuell joined Westport in May of 2022 and currently has approximately 20 years of experience in investor relations. Her career includes roles with companies at various parts of the energy sector value chain, as well as in the investor relations and stakeholder communications practice area of a global consulting firm.
This post appeared first on investingnews.com
NextSource Materials (TSX:NEXT,OTCQB:NSRCF) announced that it has signed a multi-year offtake agreement with Mitsubishi Chemical Corporation (MCC), furthering its bid to become a vertically integrated graphite supplier for the North American electric vehicle (EV) market.
Under the agreement, NextSource will supply approximately 9,000 metric tons per year of intermediate anode active material (AAM) to MCC’s plant in Japan.
MCC, Japan’s largest chemical company and a key supplier to major auto manufacturers, will refine the material into finished AAM for EV battery production in North America.
“We are excited to have entered into a partnership with Mitsubishi Chemical Corporation through a binding offtake agreement for the production of active anode material in the Middle East,” said Hanré Rossouw, President and CEO of NextSource.
The timing is also strategic. The company is fast-tracking development of a large-scale Battery Anode Facility (BAF) in the United Arab Emirates to process its proprietary SuperFlake graphite concentrate from the Molo mine in Madagascar.
The facility will serve as the production hub for the MCC agreement, with initial shipments expected following a rigorous qualification process in 2026. The company said that equipment installations are already underway and a full-scale ramp-up is targeted for 2027.
In addition to processing and logistics, NextSource is preparing for a Phase 2 expansion of the Molo mine to ensure sufficient graphite feedstock. The Madagascar-based project, which began Phase 1 operations this year, is one of the world’s highest-quality graphite deposits and the only one producing SuperFlake graphite, according to the company.
NextSource says its long-term goal is to offer a fully traceable, scalable, and China-independent source of battery-grade anode material.
The company is also in advanced talks with strategic financing partners to fund construction of the BAF and Molo expansion. Technical and economic studies are underway to determine capital requirements and investment timing.
The agreement also comes amid tightening restrictions on Chinese battery materials. In July, the US Department of Commerce imposed a 93.5 percent anti-dumping duty on anode-grade graphite imports from China, adding to existing countervailing tariffs for a combined effective rate of around 160 percent.
The decision, prompted in part by complaints from the American Active Anode Material Producers (AAAMP), was designed to shield domestic producers from what they describe as unfairly priced Chinese shipments.
The decision could reshape the graphite market, which has long been dominated by China, which is currently responsible for roughly 95 percent of global anode output. Imports from China made up two-thirds of the 180,000 metric tons of graphite shipped to the US in 2023.
Overall, there is also growing urgency among EV supply chain participants to pivot away from China.
While materials like lithium and cobalt have captured more headlines, graphite, which makes up over 95 percent of the anode side of an EV battery, is equally critical, accounting for as much as 50 kilograms per vehicle.
With the new tariffs in place, industry analysts expect a significant acceleration of non-Chinese supply chain development, particularly for US automakers under pressure to secure compliant sources.
Securities Disclosure: I, Giann Liguid, hold no direct investment interest in any company mentioned in this article.
This post appeared first on investingnews.com
Here’s a quick recap of the crypto landscape for Wednesday (August 6) as of 9:00 a.m. UTC.
Get the latest insights on Bitcoin, Ethereum and altcoins, along with a round-up of key cryptocurrency market news.
Bitcoin and Ethereum price update
Bitcoin (BTC) was priced at US$114,217, down by 0.8 percent over the last 24 hours. Its highest valuation on Wednesday was US$112,770, while its lowest valuation was US$114,830.
Bitcoin price performance, August 6, 2025.
Chart via TradingView
Bitcoin is showing signs of support between US$117,000 and US$118,000, with technical analysts suggesting a possible rebound toward resistance levels at US$120,250 and beyond, if bullish momentum builds.
However, sentiment remains cautious amid ongoing interest rate uncertainty, macroeconomic pressures and ETF outflows, all of which are weighing on near-term price action.
Ethereum (ETH) was priced at US$3,619.63, down by 1.4 percent over the past 24 hours. Its lowest valuation on Wednesday was US$3,557.78, and its highest was US$3,673.
Altcoin price update
- Solana (SOL) was priced at US$164.44, down by 3.9 percent over 24 hours. Its lowest valuation on Wednesday was US$161.45, and its highest was US$170.84.
- XRP was trading for US$2.95, down by 3.8 percent in the past 24 hours. Its lowest valuation of the day was US$2.91, and its highest valuation was US$3.06.
- Sui (SUI) is trading at US$3.41, down 4.2 percent over the past 24 hours. Its lowest valuation of the day was US$3.34, and its highest was US$3.55.
- Cardano (ADA) was trading at US$0.7274, down by 3.2 percent over 24 hours. Its lowest valuation on Wednesday was US$0.7117, and its highest was US$0.751.
Today’s crypto news to know
Bitcoin ETFs see four days of outflows as stagflation fears ramp up
Spot bitcoin ETFs in the US recorded net outflows for the fourth day in a row, shedding nearly US$200 million on Tuesday alone.
Fidelity’s FBTC and BlackRock’s IBIT were the biggest sources of withdrawals, contributing to a total outflow of US$1.46 billion since last Thursday.
The trigger appears to be rising concerns around stagflation, following weaker-than-expected US service sector data.
The ISM Non-Manufacturing PMI pointed to slowing growth, declining employment, and rising prices, which represents a toxic mix for risk assets like crypto and tech stocks.
Bitcoin slipped below US$113,000 before recovering slightly, while the Nasdaq also dropped 0.7 percent on the day.
Meanwhile, bets on Federal Reserve rate cuts are growing, but uncertainty remains high.
SBI Files Japan’s first Bitcoin–XRP ETF application
Japanese financial giant SBI Holdings has filed for an ETF that includes both Bitcoin and XRP, aiming to offer regulated dual-crypto exposure in Japan.
The proposed product, revealed in SBI’s Q2 earnings report, would allow investors to track the performance of both assets in a single fund, a rare pairing in the global ETF space.
A second ETF proposal, the Digital Gold Crypto ETF, blends over 50% exposure to traditional gold ETFs with crypto assets backed by gold. This hybrid structure targets more conservative investors looking for crypto upside with commodity stability.
If approved, this would mark the first time XRP is included in a regulated ETF product in Japan, as it continues to face institutional barriers in the US due to its regulatory history.
Liquid staking is not a securities offering — SEC clarifies
In a major development for the crypto industry, the SEC’s Division of Corporation Finance stated that certain types of liquid staking do not constitute the sale of securities, according to a statement.
Specifically, tokenized staking receipt products, such as staked ETH derivatives, are not considered investment contracts unless they’re bundled into schemes that meet the legal definition.
This clarification provides a green light for platforms offering protocol-level staking services without requiring registration. Liquid staking allows users to earn rewards while still being able to trade or use a representative token, maintaining asset flexibility.
Securities Disclosure: I, Giann Liguid, hold no direct investment interest in any company mentioned in this article.
Securities Disclosure: I, Meagen Seatter, hold no direct investment interest in any company mentioned in this article.
This post appeared first on investingnews.com
Australia could benefit from redirected global capital flows in the wake of new US tariffs under President Donald Trump — but only if it maintains its commitment to open markets, according to the country’s Productivity Commission.
In its latest Trade and Assistance Review, the commission warns against retaliatory trade measures, noting such moves would come at a cost. Deputy Chair Alex Robson has cautioned that escalation could “spiral into a broader trade war” with serious consequences for Australia and the global economy.
“Increasing our direct barriers to trade and investment, even if in retaliation, would come at a cost,” the review reads.
The report also highlights that Australia is facing its highest level of economic uncertainty since the COVID-19 pandemic. However, it notes that some of the proposed trade measures from the US could have a modest, positive effect on Australian production if the country stays on its current path.
Tariff reforms
According to the Productivity Commission, Australia is leaning toward abolishing 457 tariffs in 2025.
Still, it strongly suggests that even nuisance tariffs must go, with a total of 300 identified by the commission.
“(We believe) generate little revenue and impose high costs on business … We estimate that, in 2023-2024, the tariff regime imposed compliance costs of between AU$1.3 billion and AU$4 billion, while collecting AU$2 billion in revenue.”
The commission also illustrated the effects of abolishing tariffs, saying that this move will lead to maximizing benefits to Australian production.
“For example, if the US imposed a 10 percent tariff on all imports and Australia retaliated alongside other countries by imposing a 10 percent tariff on imports from the US, Australian GDP would be 0.14 percentage points lower than if Australia chose not to retaliate.”
In a separate analysis by Austaxpolicy, this aspect of the report was also highlighted, underlining how cheaper imports from the rest of the world, an outflow of productive capital from the US and highly tariffed economies could slightly increase Australian production.
Industry assistance
The Australian Government’s Future Made in Australia (FMIA) Act commenced in 2024, and the mining and resource industry has seen a wave of grants and support since.
“(We) found that the costs of FMIA interventions can be minimised through using alternatives or complements to domestic production. Such policy options could be explicitly considered as part of the legislated sector assessments process.”
On February 12, Australia passed the Critical Minerals Production Tax Incentive, which will provide a refundable tax credit on 10 percent of eligible costs associated with the production of critical minerals and rare earths.
“The incentives are valued at AU$7 billion over the decade,” said Federal Resources Minister Madeleine King, calling the legislation a “historic moment” for the industry.
Last April 23, Western Australia announced another round of successful applicants for its Exploration Incentive Scheme (EIS).
Among the 49 drill funding recipients are Wildcat Resources’ (ASX:WC8,OTC Pink:WDCTF) Tabba Tabba project and Western Mines Group’s (ASX:WMG) Mulga Tank, which are targeting critical minerals such as lithium, nickel and copper.
Together, all 49 companies will receive a total of AU$7.8 million as drill funding to 49 projects, while AU$3.2 million will be spread across 25 geophysics ventures. The remaining AU$200,000 will be divided between three projects under the EAP.
Australia’s Commonwealth Scientific and Industrial Research Organisation (CSIRO) also opened its doors with a new graphite research and development (R&D) program to assist small-to-medium-sized enterprises.
The initiative will allow eligible enterprises to receive up to AU$50,000 per project and collaborate with CSIRO scientists, and access quality facilities.
Expressions of interest are open until March 30, 2026.
All these and more funding efforts, according to the Productivity Commission, fall under the “behind the border” assistance, which it expects to grow further under the FMIA initiative.
“As these traditional forms of ‘at-the-border’ trade protections have receded, the relative importance of ‘behind-the-border’ industry assistance such as budgetary assistance and concessional finance has grown,” the commission explains.
Mining and numbers
According to the report, mining is among the “favoured” industries, with research and development measures as the main type of budgetary assistance.
Majority, as in 87.4 percent, of mining assistance is delivered through R&D, which is undeniable given the number of grants and government funding programs for the sector.
The commission did note that mining, alongside services, received a lower share of assistance than their share of the economy, despite receiving the greatest share of budgetary assistance in absolute terms.
For the period of 2023 to 2024, the commission found that mining remains the top destination sector for foreign direct investment (FDI) inbound to Australia, equivalent to 15 percent of gross domestic product (GDP).
However, this amount falls short of the sector’s five-year average, which is 17 percent.
It was also noted that the United States remains the largest source of FDI inbound to Australia. Following its lead are the United Kingdom, Japan, Canada and China, with their FDI equivalent to 24.8 percent of GDP.
Recent news
August opened in Australia with news that it is not listed as a country hit with a higher ‘reciprocal’ tariff under Trump’s executive order.
Trump’s tariffs on the country will remain, still on the price of 10 percent.
Minister for Trade and Tourism Don Farrell was quoted by News.com.au saying that US Commerce Secretary Howard Lutnick has been invited to Australia for continued discussions, underlining that Australia will continue to advocate for a tariff exemption.
“We believe in free and fair trade, and we will continue to put the argument to the US that they should remove all tariffs on Australian products in accordance with our free trade agreement, and we will continue to prosecute that argument.”
Securities Disclosure: I, Gabrielle de la Cruz, hold no direct investment interest in any company mentioned in this article.
This post appeared first on investingnews.com
In the latest show of federal support for domestic uranium production, Uranium Energy (NYSEAMERICAN:UEC) Sweetwater uranium complex in Wyoming has been designated for expedited permitting under the Trump administration’s FAST-41 initiative.
The designation, announced August 5, places Sweetwater on the Federal Permitting Improvement Steering Council’s FAST-41 dashboard, a move that aims to accelerate environmental reviews and interagency approvals under a framework established by the 2015 Fixing America’s Surface Transportation (FAST) Act.
The initiative is part of the Trump administration’s strategy to revitalize the US nuclear fuel supply chain and reduce reliance on imports from geopolitical rivals.
“Sweetwater’s selection under FAST-41 reinforces its national importance as a key project to achieve the United States’ goals of establishing reliable infrastructure, supporting nuclear fuel independence,” said UEC President and CEO Amir Adnani in a statement.
“On completing this tack-on permitting initiative, Sweetwater will be the largest dual-feed uranium facility in the United States, licensed to process both conventional ore and ISR resin.”
Located in Wyoming’s Great Divide Basin, the Sweetwater complex is anchored by a fully licensed conventional uranium mill with a capacity of 3,000 metric tons per day and a licensed annual output of 4.1 million pounds.
The site previously included several permitted mines—Sweetwater (Red Desert), Big Eagle, and Jackpot (Green Mountain)—that were approved for conventional methods but will now be evaluated for In-Situ Recovery (ISR) mining, a lower-impact extraction technique.
The new permitting push will allow UEC to modify existing approvals to incorporate ISR capabilities both within and beyond the current mine boundary, including on adjacent federal lands managed by the Bureau of Land Management (BLM).
The BLM, under the Department of the Interior, is the lead permitting agency for the initiative.
“This will provide the Company unrivaled flexibility to scale production across the Great Divide Basin, leveraging UEC’s leading domestic resource base,” Adnani added.
Sweetwater is the second uranium project to receive fast-track treatment under the new policy, following Anfield Energy TSXV:AEC,OTCQB:ANLDF) Velvet-Wood project in Utah, which was granted the status in May.
Velvet-Wood was the first uranium asset to be placed on the FAST-41 dashboard. It is expected to supply uranium for both civilian nuclear energy and defense applications, as well as vanadium, a strategic metal used in batteries and alloys.
Anfield’s Velvet-Wood received accelerated environmental review under a January 20 declaration by President Trump, which cited a national energy emergency and called for urgent steps to restore American energy independence. According to Anfield, the review timeline was cut from what could have taken years to just 14 days.
Taken together, the two fast-tracked uranium projects are a display of a wider federal pivot toward rebuilding a domestic nuclear supply chain, which has withered in recent decades amid low prices and competition from Russia, China, and other state-backed producers.
“I am excited to welcome the Sweetwater Complex to the FAST-41 transparency dashboard in support of President Trump’s goal of unlocking America’s mineral resources,” said Emily Domenech, Executive Director of the Federal Permitting Improvement Steering Council.
The White House confirmed in April that 10 mining projects had been selected so far under the initiative, covering minerals such as copper, gold, lithium, phosphate, potash, and uranium.
With Sweetwater, UEC will operate three hub-and-spoke uranium platforms in the United States: one in South Texas, another in Wyoming’s Powder River Basin, and the Sweetwater Complex in the Great Divide Basin.
Securities Disclosure: I, Giann Liguid, hold no direct investment interest in any company mentioned in this article.
This post appeared first on investingnews.com
First Quantum Minerals (TSX:FM,OTC Pink:FQVLF) has locked in a US$1.0 billion cash infusion through a gold streaming agreement with RGLD Gold AG, a wholly owned subsidiary of Royal Gold (NASDAQ:RGLD).
The Vancouver-based firm announced on Tuesday (August 5) that the streaming agreement is tied to its Zambian operations, covering future gold deliveries linked to copper output at its Kansanshi mine.
“Following a thorough evaluation of several deleveraging options, I am pleased to announce this milestone transaction which preserves exposure to all of the copper production at Kansanshi while still maintaining exposure to the majority of the Company’s gold production,” said First Quantum CEO Tristan Pascall in a press release.
“It is pleasing to form a new partnership with Royal Gold which is a strong endorsement of the operations at Kansanshi and its multi-generational ore body as well as Zambia as a leading African mining jurisdiction,” Pascall added.
The agreement provides First Quantum with long-term, unsecured capital that does not increase its debt load. Proceeds will be used for capital expenditures and repayment of existing bank loans. Furthermore, the company said that the transaction is expected to materially lower its net debt-to-EBITDA ratio.
While the arrangement commits First Quantum to deliver gold based on a formula tied to copper production, the company retains most of its gold upside.
Based on its 2026 and 2027 production forecasts, approximately 84 percent of its total gold output will still be exposed to spot market pricing. The company also retains full exposure to newly discovered near-surface gold zones at Kansanshi.
Under the terms of the agreement, First Quantum will deliver gold to Royal Gold on a stepdown basis: 75 ounces of gold for every million pounds of recovered copper produced until 425,000 ounces have been delivered, 55 ounces per million pounds for the next 225,000 ounces, and 45 ounces per million pounds thereafter.
First Quantum will receive 20 percent of the spot gold price per ounce delivered, rising to 35 percent if it secures a BB credit rating or maintains a net leverage ratio of 2.25x or lower for three straight quarters starting Q1 2026.
The deal also includes two optional acceleration provisions, allowing First Quantum to reduce future delivery commitments. The company can cut delivery thresholds by up to 20 percent at a value of up to US$200 million once it reaches the BB rating or leverage target.
A further 10 percent reduction, worth US$100 million, is possible upon achieving a leverage ratio of 1.25 times over four consecutive quarters, subject to meeting certain operational conditions.
The gold streaming deal is part of First Quantum’s continued efforts to strengthen its finances after recent setbacks at the Cobre Panamá mine.
In May, the company announced it had received government approval in Panama for its Preservation and Safe Management program at the Cobre Panamá mine. The approval enables the company to carry out environmental and safety measures funded through the export of 121,000 dry metric tons of copper concentrate currently stored on site.
The program does not represent a restart of full operations, but allows First Quantum to maintain the site and manage its obligations in line with Panamanian government requirements.
On the other hand, the deal also deepens Royal Gold’s exposure to a major African copper-gold asset at a time when the streaming and royalty company is making moves to expand its portfolio.
Just last month, Royal Gold announced a pair of major acquisitions: a US$3.5 billion all-share deal to acquire Sandstorm Gold (TSX:SSL)and a separate US$196 million cash deal for Horizon Copper (TSXV:HCU).
The transactions, announced in July, would create a streaming and royalty giant with 393 assets across six continents—including 80 that are currently cash-flowing.
Shares of First Quantum were up slightly in Tuesday trading following the announcement.
Securities Disclosure: I, Giann Liguid, hold no direct investment interest in any company mentioned in this article.
This post appeared first on investingnews.com
Here’s a quick recap of the crypto landscape for Wednesday (August 6) as of 9:00 a.m. UTC.
Get the latest insights on Bitcoin, Ethereum and altcoins, along with a round-up of key cryptocurrency market news.
Bitcoin and Ethereum price update
Bitcoin (BTC) was priced at US$114,217, down by 0.8 percent over the last 24 hours. Its highest valuation on Wednesday was US$112,770, while its lowest valuation was US$114,830.
Bitcoin price performance, August 6, 2025.
Chart via TradingView
Bitcoin is showing signs of support between US$117,000 and US$118,000, with technical analysts suggesting a possible rebound toward resistance levels at US$120,250 and beyond, if bullish momentum builds.
However, sentiment remains cautious amid ongoing interest rate uncertainty, macroeconomic pressures and ETF outflows, all of which are weighing on near-term price action.
Ethereum (ETH) was priced at US$3,619.63, down by 1.4 percent over the past 24 hours. Its lowest valuation on Wednesday was US$3,557.78, and its highest was US$3,673.
Altcoin price update
- Solana (SOL) was priced at US$164.44, down by 3.9 percent over 24 hours. Its lowest valuation on Wednesday was US$161.45, and its highest was US$170.84.
- XRP was trading for US$2.95, down by 3.8 percent in the past 24 hours. Its lowest valuation of the day was US$2.91, and its highest valuation was US$3.06.
- Sui (SUI) is trading at US$3.41, down 4.2 percent over the past 24 hours. Its lowest valuation of the day was US$3.34, and its highest was US$3.55.
- Cardano (ADA) was trading at US$0.7274, down by 3.2 percent over 24 hours. Its lowest valuation on Wednesday was US$0.7117, and its highest was US$0.751.
Today’s crypto news to know
Bitcoin ETFs see four days of outflows as stagflation fears ramp up
Spot bitcoin ETFs in the US recorded net outflows for the fourth day in a row, shedding nearly US$200 million on Tuesday alone.
Fidelity’s FBTC and BlackRock’s IBIT were the biggest sources of withdrawals, contributing to a total outflow of US$1.46 billion since last Thursday.
The trigger appears to be rising concerns around stagflation, following weaker-than-expected US service sector data.
The ISM Non-Manufacturing PMI pointed to slowing growth, declining employment, and rising prices, which represents a toxic mix for risk assets like crypto and tech stocks.
Bitcoin slipped below US$113,000 before recovering slightly, while the Nasdaq also dropped 0.7 percent on the day.
Meanwhile, bets on Federal Reserve rate cuts are growing, but uncertainty remains high.
SBI Files Japan’s first Bitcoin–XRP ETF application
Japanese financial giant SBI Holdings has filed for an ETF that includes both Bitcoin and XRP, aiming to offer regulated dual-crypto exposure in Japan.
The proposed product, revealed in SBI’s Q2 earnings report, would allow investors to track the performance of both assets in a single fund, a rare pairing in the global ETF space.
A second ETF proposal, the Digital Gold Crypto ETF, blends over 50% exposure to traditional gold ETFs with crypto assets backed by gold. This hybrid structure targets more conservative investors looking for crypto upside with commodity stability.
If approved, this would mark the first time XRP is included in a regulated ETF product in Japan, as it continues to face institutional barriers in the US due to its regulatory history.
Liquid staking is not a securities offering — SEC clarifies
In a major development for the crypto industry, the SEC’s Division of Corporation Finance stated that certain types of liquid staking do not constitute the sale of securities, according to a statement.
Specifically, tokenized staking receipt products, such as staked ETH derivatives, are not considered investment contracts unless they’re bundled into schemes that meet the legal definition.
This clarification provides a green light for platforms offering protocol-level staking services without requiring registration. Liquid staking allows users to earn rewards while still being able to trade or use a representative token, maintaining asset flexibility.
Securities Disclosure: I, Giann Liguid, hold no direct investment interest in any company mentioned in this article.
Securities Disclosure: I, Meagen Seatter, hold no direct investment interest in any company mentioned in this article.
This post appeared first on investingnews.com
Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (‘Cardiol‘ or the ‘Company‘), a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, today announced topline results from ARCHER, the Company’s Phase II clinical trial in patients with acute myocarditis. In the two primary endpoints—extracellular volume (‘ECV’) and global longitudinal strain (‘GLS’)—CardiolRx
showed a notable improvement in ECV (p = 0.0538) compared to placebo following 12 weeks of double-blind therapy, with no significant difference observed in GLS in a population that had preserved left ventricular (‘LV’) function at baseline. The reduction in ECV was associated with improvements over placebo in multiple pre-specified cardiac magnetic resonance imaging (‘CMR’) endpoints, including a significant reduction in LV mass. The ARCHER trial results provide compelling clinical proof of concept for CardiolRx and strongly support advancing the clinical development of CardiolRx and CRD-38 in cardiomyopathies, heart failure, and myocarditis. Consistent with findings from Cardiol’s Phase II MAvERIC trial in recurrent pericarditis, CardiolRx was shown to be safe and well tolerated. The ARCHER results have been submitted for presentation at an upcoming scientific meeting and will be submitted for publication.
- Change in the primary endpoint of left ventricular (LV) extracellular volume (ECV) showed a notable improvement (p = 0.0538) favouring CardiolRx over placebo.
- Reduction in ECV was associated with improvements across multiple pre-specified cardiac magnetic resonance imaging (CMR) endpoints, including a significant reduction in LV mass.
- The ARCHER trial results provide compelling clinical proof of concept for CardiolRx and strongly support advancing the clinical development of CardiolRx and CRD-38 in cardiomyopathies, heart failure, and myocarditis.
- The ARCHER results have been submitted for presentation at an upcoming scientific meeting and will be submitted for publication.
‘On behalf of the ARCHER Steering Committee, I would like to extend our sincere gratitude to the patients who participated in the study; to their families and caregivers for their invaluable support; and to the clinical trial site investigators and staff, members of the international Steering Committee, and the Data and Safety Monitoring Committee, whose exemplary efforts in patient recruitment, clinical care, trial execution, monitoring, and oversight were instrumental in achieving the compelling findings of the ARCHER trial,’ said Dr. Dennis M. McNamara, Professor of Medicine at the University of Pittsburgh, Director of the Center for Heart Failure Research at the University of Pittsburgh Medical Center, and Chair of the ARCHER Steering Committee. ‘I commend Cardiol for undertaking this important trial that investigated the biological effects of pharmaceutically manufactured cannabidiol in acute myocarditis. The results offer exciting new insights into the treatment of acute myocarditis and strongly support advancing the clinical development of this novel therapeutic approach for inflammatory cardiac conditions, including myocarditis and heart failure. I look forward to collaborating with my colleagues on the Steering Committee as we prepare for the presentation and publication of the comprehensive ARCHER trial data.’
Dr. Leslie T. Cooper, Jr., the Elizabeth C. Lane, Ph.D. and M. Nadine Zimmerman, Ph.D. Professor of Internal Medicine at the Mayo Clinic in Jacksonville, Florida, and Co-Chair of the Steering Committee for the ARCHER trial, added, ‘ARCHER was an important, well-designed, and well-executed clinical trial. The intriguing findings reinforce our original hypothesis that pharmaceutically manufactured cannabidiol can attenuate myocardial inflammation and edema. ARCHER’s results provide sound rationale for advancing the clinical development of this novel therapy in conditions of the myocardium characterized by edema, fibrosis, and remodeling, including the growing challenge of immune checkpoint inhibitor-induced myocarditis which can be fatal.’
‘We are delighted with the ARCHER trial results,’ said David Elsley, President and Chief Executive Officer of Cardiol Therapeutics. ‘We initiated this ambitious study—focused on a potentially life-threatening cardiac disorder for which there is no established standard of care—to further investigate the therapeutic potential of CardiolRx in inflammatory heart disease. We are thrilled to observe improvements in multiple CMR measures associated with diagnosis, prognosis, and clinical outcomes. As we continue to advance our lead clinical program, the pivotal Phase III MAVERIC trial in recurrent pericarditis, we now look forward to integrating the ARCHER findings into our broader clinical development strategy and business development initiatives—supporting the continued advancement of CardiolRx and CRD-38 as potential treatments for inflammatory cardiac disorders.’
ARCHER is a Phase II multi-national, randomized, double-blind, placebo-controlled trial investigating the safety, tolerability, and impact of CardiolRx on myocardial recovery in patients presenting with acute myocarditis. The design and rationale for ARCHER were published on June 27, 2024, in the journal ESC Heart Failure. The study enrolled 109 patients from leading cardiovascular research centers in the United States, France, Brazil, and Israel. The two primary outcome measures of the trial, which were evaluated following 12 weeks of double-blind therapy, consist of cardiac magnetic resonance imaging parameters: extra-cellular volume and global longitudinal strain, which assess myocardial function and tissue characteristics associated with fibrosis and inflammation.
Acute Myocarditis
Acute myocarditis is an inflammatory condition of the heart muscle (myocardium) characterized by chest pain, shortness of breath at rest or during activity, fatigue, rapid or irregular heartbeat (arrhythmias), and light-headedness or the feeling one might faint. The disease is an important cause of acute and fulminant heart failure and is a leading cause of sudden cardiac death in people under 35 years of age. Viral infection is the most common cause of myocarditis; however, it can also result from bacterial infection, commonly used drugs, and mRNA vaccines, as well as therapies used to treat several common cancers, including chemo-therapeutic agents and immune checkpoint inhibitors. There are no FDA-approved drug therapies for acute myocarditis. Patients hospitalized with the condition experience an average seven-day length of stay and a 4 – 6% risk of in-hospital mortality, with average hospital charge per stay estimated at $110,000 in the United States.
About Cardiol Therapeutics
Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) is a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company’s lead small molecule drug candidate, CardiolRx (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It is recognized that cannabidiol inhibits activation of the inflammasome pathway, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with pericarditis, myocarditis, and heart failure.
Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration (‘US FDA’) to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart: recurrent pericarditis and acute myocarditis. The MAVERIC Program in recurrent pericarditis, an inflammatory disease of the pericardium which is associated with symptoms including debilitating chest pain, shortness of breath, and fatigue, and results in physical limitations, reduced quality of life, emergency department visits, and hospitalizations, comprises the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing Phase III MAVERIC trial (NCT06708299). The completed ARCHER trial (NCT05180240) is a Phase II study in acute myocarditis, an important cause of acute and fulminant heart failure in young adults and a leading cause of sudden cardiac death in people less than 35 years of age. The US FDA has granted Orphan Drug Designation to CardiolRx for the treatment of pericarditis, which includes recurrent pericarditis.
Cardiol is also developing CRD-38, a novel subcutaneously administered drug formulation intended for use in heart failure—a leading cause of death and hospitalization in the developed world, with associated healthcare costs in the United States exceeding $30 billion annually.
For more information about Cardiol Therapeutics, please visit cardiolrx.com.
Cautionary statement regarding forward-looking information:
This news release contains ‘forward-looking information’ within the meaning of applicable securities laws. All statements, other than statements of historical fact, that address activities, events, or developments that Cardiol believes, expects, or anticipates will, may, could, or might occur in the future are ‘forward-looking information’. Forward-looking information contained herein may include, but is not limited to statements regarding the Company’s focus on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, the Company’s intended clinical studies and trial activities and timelines associated with such activities, including the Company’s plan to complete the Phase III study in recurrent pericarditis with CardiolRx, the Company’s plan to advance the development of CRD-38, a novel subcutaneous formulation of cannabidiol intended for use in heart failure, the Company’s presentation and publication of the comprehensive ARCHER trial data, and the Company’s belief that results from the ARCHER trial provide compelling clinical proof of concept for CardiolRx and strongly support advancing the clinical development of CardiolRx and CRD-38 for the treatment of inflammatory cardiac disorders including cardiomyopathies, heart failure, and myocarditis. Forward-looking information contained herein reflects the current expectations or beliefs of Cardiol based on information currently available to it and is based on certain assumptions and is also subject to a variety of known and unknown risks and uncertainties and other factors that could cause the actual events or results to differ materially from any future results, performance or achievements expressed or implied by the forward looking information, and are not (and should not be considered to be) guarantees of future performance. These risks and uncertainties and other factors include the risks and uncertainties referred to in the Company’s Annual Information Form filed with the Canadian securities administrators and U.S. Securities and Exchange Commission on March 31, 2025, available on SEDAR+ at sedarplus.ca and EDGAR at sec.gov, as well as the risks and uncertainties associated with product commercialization and clinical studies. These assumptions, risks, uncertainties, and other factors should be considered carefully, and investors should not place undue reliance on the forward-looking information, and such information may not be appropriate for other purposes. Any forward-looking information speaks only as of the date of this press release and, except as may be required by applicable securities laws, Cardiol disclaims any intent or obligation to update or revise such forward-looking information, whether as a result of new information, future events, or results, or otherwise. Investors are cautioned not to rely on these forward-looking statements.
For further information, please contact:
Trevor Burns, Investor Relations +1-289-910-0855
trevor.burns@cardiolrx.com
Click here to connect with Cardiol Therapeutics Inc. to receive an Investor Presentation
Source
This post appeared first on investingnews.com